依替巴肽在急性ST段抬高型心肌梗死患者急诊PCI术中的应用效果分析

Analysis of the Effect of Eptifibatide in Emergency PCI in Patients with Acute ST-segment Elevation Myocardial Infarction

目的探究冠状动脉内应用依替巴肽在急性ST段抬高型心肌梗死患者急诊PCI术中的应用效果分析。方法选取2019年6月—2020年12月期间该院心血管内科收治的80例ST段抬高型心肌梗死患者为研究对象。按随机数表法分为对照组(40例)与研究组(40例),两组均行急诊PCI,对照组开通血管后常规静脉使用替罗非班,研究组开通血管后冠状动脉内应用依替巴肽,对比两组急性心梗患者的术后血流及住院期间治疗效果。结果研究组总有效率为93%高于对照组的75%,差异有统计学意义(χ^(2)=4.501,P<0.05);研究组并发症发生率低于对照组,差异有统计学意义(P<0.05);研究组生活质量评分优于对照组,差异有统计学意义(P<0.05)。研究组血小板聚集率为(3.24±0.49)%,明显低于对照组,两组比较差异有统计学意义(P<0.05);研究组左心射血分数为(64.79±2.39)%、左心室舒张末期内径为(51.73±3.22)cm、B型钠尿肽数值为(46.98±3.12)pg/mL,明显优于对照组,两组比较差异有统计学意义(P<0.05)。结论冠状动脉内应用依替巴肽具有较为突出的临床效果,能够减轻患者血栓负荷,减少冠脉慢血流及无复流,进一步降低术中及术后心血管事件的发生,具有较高的临床价值,值得临床推广应用。

Objective To explore the effect of intracoronary application of eptifibatide in emergency PCI for patients with acute ST-segment elevation myocardial infarction.Methods Selected 80 patients with ST-segment elevation myocardial infarction admitted to the hospital's Department of Cardiology from June 2019 to December 2020 as the research subjects.The control group(40 cases)and the study group(40 cases)were divided according to the random number table method,and both groups underwent emergency PCI.Tirofiban was routinely administered intravenously after opening the blood vessel in the control group,and eptifibatide was used in the coronary artery after opening the blood vessel in the study group.The postoperative blood flow of the two groups of patients with acute myocardial infarction and the treatment effect during hospitalization were compared.Results The total effective rate of the study group was 93%,which was higher than 75%of the control group,and the difference was statistically significant(χ^(2)=4.501,P<0.05);The incidence of complications in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05);The quality of life score of the study group was better than that of the control group,and the difference was statistically significant(P<0.05).The platelet aggregation rate of the study group was(3.24±0.49)%,which was significantly lower than that of the control group,and the difference between the two groups was statistically significant(P<0.05).The left ventricular ejection fraction of the study group was(64.79±2.39)%,the end-diastolic diameter of the left ventricle was(51.73±3.22)cm,and the value of B-type natriuretic peptide was(46.98±3.12)pg/mL,significantly better than the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion The application of eptifibatide in the coronary arteries has a relatively prominent clinical effect,which can reduce the patient's thrombotic load,reduce slow coronary blood flow and no reflow,and further reduce the occurrence of intraoperative and postoperative cardiovascular events.It has high clinical value and is worthy of clinical application.